loader image

Kelso Pharma appoints Life Sciences leader as Chairman

Kelso Pharma, the growing specialty pharma business, has appointed senior Life Sciences executive, Gordon Cameron OBE, as its Non-Executive Chairman.

A senior executive with 25 years’ Board-level experience in private equity and plc listed businesses, Gordon has worked in the UK and US, primarily in biotech and pharmaceutical services including both contract research organisations (CRO) and contract development and manufacturing organisations (CDMO). Originally with Ernst & Young, Gordon had several years in investment banking with Rothschild before becoming CFO and then CEO of FTSE-250 international vaccines company, Acambis plc.  Gordon has spent the last 15 years as CFO with Quotient Sciences, a private-equity backed international CDMO and CRO. During his time there, revenues grew 15-fold.

Kelso Pharma aims to bring innovative, value-added, specialty medicines to the European healthcare markets, providing medicines that improve the lives of patients in a cost-effective and ethical manner. Kelso Pharma is growing through a blend of company & product acquisitions, partnerships and organic growth, both in the UK and in Europe.

Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, said:

“We’re thrilled to welcome Gordon to the Kelso Pharma team as our Non-Executive Chairman. He brings extensive industry experience, as well as a deep understanding of growing businesses under private equity ownership.

“Gordon’s experience, skillset and knowledge demonstrate the calibre of people we’re looking to work with at Kelso Pharma. We aim to provide medicines that improve the lives of patients on a daily basis and we look forward to working with Gordon as we continue to grow the business.”

Gordon Cameron added: “I’m very excited to be joining Kelso Pharma at a busy and pivotal time for the business as they look to grow, both organically and by acquisition.

“With the aim of providing value-added medicines to the market in an ethical manner with people at the heart of decision making aligns with my own values and I’m looking forward to playing a part in driving Kelso Pharma’s growth.”

Related News

June 25, 2024

Stirling Anglian Pharmaceuticals launches new website with focus on providing patients with value-based solutions to healthcare

January 8, 2024

Kelso Pharma closes acquisition of Italian specialty pharma company, Velit Biopharma

December 14, 2023

Kelso Pharma announces strategic partnerships with PharmaPath and Valpharma